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Abstract 
There is increasing clinical use of combined positron emission tomography (PET) and magnetic 
resonance imaging (MRI) but to date there has been no clinical system developed capable of 
simultaneous single photon emission computed tomography (SPECT) and MRI. There has been 
development of preclinical systems but there are several challenges facing researchers who are 
developing a clinical prototype including the need for the system to be compact and stationary with 
MRI-compatible components. The limited work in this area is described with specific reference to 
the INSERT project which is at an advanced stage of developing a clinical prototype. Issues of 
SPECT/MRI compatibility are outlined and the clinical appeal of such a system is discussed, especially 
in the management of brain tumour treatment.  
Introduction 
Hybrid clinical systems with the combination of x-ray computed tomography (CT) and either single 
photon emission computed tomography (SPECT) or positron emission tomography (PET) have been 
commercially available since 1999/2000 and have found important roles in clinical practice [1]. The 
combination of clinical PET with magnetic resonance imaging (MRI) was more recent, necessitating 
the development of MRI-compatible components that support simultaneous acquisition [2-4]. At the 
time of writing, however, the combination of SPECT and MRI in a simultaneous clinical system has 
yet to be achieved, although work is in progress to produce a functional prototype. This article 
provides an overview of this relatively new area of development and insight to the challenges facing 
researchers who are actively developing these systems. The coverage will summarize the limited 
literature on SPECT/MRI technology,  using as an example the clinical design adopted in an ongoing 
project (INSERT) funded under the European Commission (EC) FP7 framework. In this project the 
researchers aim to construct the world’s first prototype clinical brain SPECT insert suitable for 
simultaneous use with an existing MRI. As in the case of the first clinical PET/MRI systems which 
were dedicated brain PET inserts, this system is a first step towards the potential development of a 
whole body SPECT system which would have wider application. 
There are some major technological challenges in achieving truly simultaneous SPECT/MRI, not least 
the need for MRI-compatibility and MRI-safety of components and electronics. Similar challenges 
have faced developers of PET/MRI, with the adoption of MRI-compatible readout as replacement for 
the conventional photomultiplier tube [5, 6]. However, the need for compact detectors that include 
collimation and stationary tomographic acquisition impose additional constraints on the MRI-
compatible SPECT system design. A sequential preclinical SPECT/MRI system is already commercially 
available and a number of preclinical synchronous SPECT/MRI experimental systems have been built 
in recent years, but these tend to rely on pinhole collimation with magnification which mainly suits 
small objects [7-9]. Developing a clinical system has required considerable innovation in many 
aspects of the design.    
This paper is structured as follows. The options for detector design are discussed, including 
description of customised silicon photo-multipliers (SiPM) designed specifically for use in SPECT. The 
possible collimator designs and overall system design are discussed and MRI compatibility of 
components including electronics is considered. Finally the potential applications of such systems 
are presented along with a brief discussion on the pros and cons of such a system.   
Revised Manuscript - Clean
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SPECT detectors for simultaneous SPECT/MRI   
In the case of the early development of PET/MRI, a compact brain PET insert was designed that 
could be utilised with an existing commercial MRI system [10]. This then led to the development of 
more integrated systems suitable for whole body scanning [11]. A similar strategy for the 
development of SPECT/MRI can be adopted. One of the major constraints to be solved in the 
development of an integrated SPECT/MRI system is the design of a compact gamma-detection 
module which exhibits mutual compatibility with commercial MRI scanners. Photomultiplier tubes 
(PMTs) are the photodetectors most commonly used in conventional SPECT systems. Unfortunately, 
PMT arrays are too bulky to be fitted inside an MRI bore and their performance is severely affected 
by the high magnetic field and the pulsed magnetic field gradients used in MRI. Several solutions 
have been suggested. A first approach considers the placement of magnetic-sensitive devices, such 
as PMTs, far enough from the MRI apparatus, and to carry the light from the scintillators to the 
photo detectors through long optical fibres [12, 13]. Another approach is based on the adoption of 
either pixelated solid state detectors (e.g. Cadmium Telluride (CdTe), Cadmium Zinc Telluride 
(CdZnTe or CZT)) [7, 14-16] or inorganic scintillators coupled to solid state photodetectors (e.g. 
avalanche photodiodes (APDs) or Silicon Photmultipliers(SiPMs)) [17-19].  Digital SiPM technology 
has also been developed where on-chip circuitry enables fast, accurate photon counting and well-
defined timing [20]. In combination with compact readout electronics, these solutions provide 
compatibility with high magnetic fields and compact designs that are suitable for use within MRI 
bore sizes of 60 cm to 70 cm commonly used in clinical practice.  
 
A strong case has been made for the adoption of SPECT/MRI for preclinical use [14]. In most of the 
experimental synchronous preclinical SPECT/MRI systems under study, arrays of CdTe and CdZnTe 
(CZT) gamma detectors are employed, e.g [21, 22]. Similar solid state technology is finding increasing 
use in clinical SPECT systems being used for cardiac imaging [23, 24], scinti-mammography [25] and, 
more recently, whole body SPECT imaging [26]. As regards compatibility with MRI, preliminary 
investigations on CdTe and CZT have shown that a shift of the signal charge inside the detector 
caused by Lorentz forces takes place and this phenomenon requires correction to improve the 
detector response so as to achieve high resolution [9].  
 
An alternative for use in SPECT/MRI is the employment of SiPMs to read out the light emitted by 
inorganic scintillators [27]. Beyond the wide success of such detectors in MR compatible PET systems 
[28-30], there are several SPECT development projects reported in the literature, exploring SiPM-
based gamma detector modules [31-34]. The goal of these researchers was to produce compact 
gamma cameras for use in surgery or small organ imaging. These systems have not normally been 
developed specifically for MRI compatibility and are not tomographic, but similar compact 
technology could be adapted for use in synchronous SPECT/MRI. SiPMs show no intrinsic sensitivity 
to magnetic fields, an important argument for the usage of a SiPM-based gamma camera in 
combination with MRI [6]. Although the energy resolution of a scintillation-based system is typically 
inferior to that offered by CdTe and CZT it is still adequate to potentially allow specific clinically 
important multi-radionuclide acquisitions (e.g. 99mTc and 111In, 99mTc and 201Tl).  
 
A disadvantage of pixelated detectors is that they involve direct readout for each pixel; the number 
increases as pixel size is decreased. In comparison a SiPM readout system with multiplexing requires 
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a relatively small number of direct electrical connections since the readout units are quite large 
compared to the resolution (at least an order of magnitude larger). This opens the possibility to 
reach a given spatial resolution with a significant reduction in the number of electronics readout 
channels (a factor of one hundred) compared to a pixelated detector with the pixel size equal to the 
desired resolution [38]. This advantage will be particularly important in the translation of this 
technology for clinical application. For a scintillator in combination with SiPMs, sufficiently high 
intrinsic spatial resolution is achievable (~1mm) to enable compact SPECT designs, taking advantage 
of multiple apertures with minification (see section below) [35-37].  
 
SPECT/MRI system design 
Sequential SPECT and MRI imaging has been performed with a small animal SPECT adjacent to a low 
field (0.1T) MRI system [39], a solution still limited by the lack of simultaneity and by the need for a 
low magnetic field. Several groups have designed MRI compatible preclinical systems. The design of 
an MRI-compatible SPECT system for mouse brain imaging has been presented together with results 
of the effect of SPECT and MRI components on each other [7]. This early development led to more 
recent construction of an ultrahigh resolution stationary MRI compatible SPECT system for small 
animal imaging, based on CdTe/CdZnTe detectors [22]. Further preclinical systems have been 
developed through academic/industrial collaborations and the SPECT-MRI interaction has been 
evaluated [8, 40-42]. A preclinical SPECT system has been designed using LYSO and dSiPMs [43]; the 
high density detector enables use of a thin detector for SPECT with potential to reduce depth of 
interaction effects that are common with pinhole collimation. However the light output is somewhat 
compromised for low energy gamma emitters. A preclinical prototype based on SiPM readout has 
also been developed in the INSERT project [44], with modular detectors that also suit a clinical SPECT 
design (see Figure 1 and further detail below).  First images from the preclinical system have been 
recently demonstrated [10].  
 
At the time of writing the only commercially available preclinical SPECT/MRI system (nanoScan® 
SPECT/MRI 1T, Mediso, Budapest) is an in-line sytem that uses a combination of high-resolution 
multi-pinhole apertures, a PMT-based conventional SPECT detection module and a specially 
developed shielding system combined with a self-shielded 1T permanent magnet. This combination 
has proven to yield high SPECT image quality and high resolution imaging possibilities coupled to a 
user-friendly and biologically relevant series of MRI sequences. However in-line SPECT/MRI still lacks 
the advantages presented by synchronous SPECT and MRI acquisition. 
At the time of writing there is publication of only one clinical SPECT/MRI under construction (INSERT) 
[25], dedicated to human brain imaging. The system has been designed using stationary rings of 
detector modules, designed so as to minimize variation in the components when translating from 
the preclinical to the clinical configuration. The electronic board, for SiPM signal processing and 
transmission through optical fibres, also provides the mechanical support for a modular number of 
compact SiPM arrays supplied by FBK, Trento [44]. The SiPM arrays are arranged in tiles to cover the 
required detector area: 5 × 5 cm2 for the preclinical configuration and 10 × 5 cm2 in the clinical case 
(Figure 2). An 8 mm thick CsI(Tl) monolithic scintillator is optically coupled over the overall SiPM 
matrix surface.  
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The detection module performance is mainly determined by the amount of light detected by the 
SiPM array. Since SPECT involves use of radionuclides with relatively low emission energy, a low 
amount of light is generated for any scintillation event. Thus the following design principles have 
been employed:  
1. A CsI(Tl) scintillator has been adopted. CsI has a high light output and, although it is one of 
the slowest inorganic crystals, the timing performance of the camera is sufficient to handle 
the expected clinical countrate. 
2. The gaps between SiPM cells has been minimized through a set of smart strategies in SiPM 
alignment [44]. As a result, loss in light detection has been significantly reduced. 
3. SiPM technology with optimal optical detection efficiency has been chosen, specifically 
adapted to the optical wavelength for CsI scintillation.  
At room temperature the presence of thermal noise results in deterioration of the energy resolution, 
necessitating cooling of the SiPM array. The detector module therefore incorporates a compact 
8mm thick cooling block made of MR-compatible thermoplastic (Coolpoly, Celanese), placed 
between the SiPM array and the electronic readout board and designed to ensure uniform 
temperature control over the SiPM area ( Figure 3). A glycol/ water mixture is circulated to maintain 
operating temperature of 0 degrees Celsius. Image quality over the single gamma-detection module 
has been tested with 99mTc (Figure 4). The intrinsic spatial resolution of the device is approximately 
1.0 mm FWHM over a planar field of view of slightly more than 4 × 4 cm2.  
The clinical system design is illustrated in Figure 5. This is based on use of twenty detector modules 
arranged in a partial ring, designed to maximize the patient aperture with minimal alteration to the 
existing patient bed. Key to the development has been the choice of a collimator which has been 
designed to provide maximum axial coverage and optimal sensitivity, while maintaining 
reconstructed resolution so as to be similar to conventional gamma camera SPECT. The reason for 
this target was the intention to explore the use of the technology to characterize and evaluate 
treatment in well-identified brain tumours rather than to optimize detection of small abnormalities. 
 
Collimators for compact clinical systems 
The design of a compact clinical system is markedly different from the typical preclinical designs 
where multipinhole systems usually take advantage of magnification to achieve superior resolution. 
With improvement in intrinsic resolution the degree of magnification can be reduced so as to 
achieve the desired compact design. Similar designs have been adopted to achieve superior 
resolution for clinical brain SPECT (MiLabs: G-SPECT, Mediso: Anyscan Trio), however these systems 
are not compact. Instead, the improvement of intrinsic resolution using the new technology can be 
used to advantage by adopting minification as opposed to magnification so that the resolution is 
effectively traded against compactness, to achieve similar performance to a conventional gamma 
camera SPECT system.  
The main challenges in collimator design are to construct a compact system with sufficient angular 
sampling to permit stationary acquisition (avoiding detector movement is highly desirable for 
simultaneous SPECT/MRI acquisition). Van Audenhaege et al. proposed a design for a multi-pinhole 
collimator for performing clinical brain SPECT studies using an existing PET scanner [45]. The 
collimator was equipped with a shutter mechanism, in order to eliminate the need for rotation, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
PR
OO
FS
BJ
R 
UN
CO
RR
EC
TE
D 
5 
 
however the prototype was not MR-compatible. Preclinical systems usually utilise multi-pinhole 
collimators [46, 47] but for a compact clinical system preference was given to utilizing a multi-slit-
slat collimator (Figure 6) which incorporates several novel features. The slits are located internal to 
the slats so as to achieve the desired minification without compromising slat length (which controls 
the axial resolution / sensitivity tradeoff). Multiple short slits are employed to improve the angular 
sampling and slits are shared across detectors so as to accommodate the desired field of view. The 
resulting collimator [37] demonstrates higher sensitivity than alternative multi-pinhole collimators 
and improves also on fan-beam collimation which is commonly used on conventional SPECT.  
A further consideration in collimator design is the choice of material and the avoidance of features 
which might result in induced eddy currents (see section below). The rapid switching of gradient 
coils induces spatially and temporally varying eddy currents within the conducting structures of the 
MRI scanner and in the collimator required for SPECT, which typically has a high conductivity. The 
undesired magnetic field produced by these eddy currents opposes and distorts the linear gradient 
fields in the region of interest, which results in image artifacts [48]. Other effects concern the 
thermal load in the cryostat of the superconducting magnet, which may lead to increased boil-off of 
the cryogens (can even cause magnetic quenching in extreme cases) and acoustic noise due to their 
interaction with the B0 field [49]. The material traditionally used for collimators and shielding is lead, 
strengthened by various impurities that tend to be ferromagnetic. The alternative is to use Tungsten 
and several groups have developed tungsten/epoxy composites in an attempt to reduce eddy 
currents while maintaining stopping power [50]. This strategy works well for radiation shielding, with 
attenuation approaching that of lead being possible. However the composite material tends to be 
brittle and easily broken and so not suitable for fine collimator components.  
Various strategies can be employed in the design of pinhole collimators to reduce the incidence of 
eddy currents e.g. segmenting the collimator into smaller subsections while avoiding any possible 
penetration [51]. Manufacturing the resulting complex parts is greatly aided by recent developments 
in additive manufacturing [52]. In the case of already complex multi-component tungsten 
collimators (e.g. multi-slit-slat collimators) induced eddy currents appear to be acceptably small.  
SPECT/MRI compatibility 
The technical challenges of integrating a SPECT insert with a clinical MRI system relate primarily to 
potential interferences between both modalities. These interferences might compromise MR safety 
and MR compatibility. The requirements of MR safety are met if the SPECT device poses no known 
hazards in a specified MRI environment with specified conditions of use. Conditions that define the 
MRI environment include static magnetic field strength, spatial magnetic field gradient, time varying 
magnetic fields and radiofrequency (RF) power deposition. Additional conditions, including specific 
configurations of the SPECT device (e.g., routing of leads and power lines), may be required. MR 
compatibility indicates that a SPECT device, when used in the MR environment, does not significantly 
reduce the quality of the diagnostic information via the formation of MR signal and image artifacts, 
and that its operation will not be detrimentally affected by the MR device.  
Mutual SPECT/MRI safety and compatibility issues may arise from: 
 Static magnetic fields (B0): Interference with the B0 spatial gradient can cause displacement and 
torque of objects moved into the MR environment. This displacement force is responsible for 
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the projectile effect that continues to cause accidents in the MR environment. Diagnostic MRI 
and MR spectroscopy require a B0 uniformity of ≤ 1 ppm and foreign objects such as bulk 
collimators, SPECT detector modules and large bundles of leads placed in the MR magnet run 
the potential to perturb B0. The static magnetic field might also induce susceptibility effects 
which bear the risk to spoil MR signal and image quality if placed close to the field-of-view used 
for MRI. Sensitivity to B0 might also cause mal- and dysfunction of the SPECT device due to 
electromagnetic interference with its electronics and detectors. 
 Switching magnetic fields (dB/dt: ≤200 mT/m/ms): Switching magnetic fields can cause 
movement, frequency shift and temperature rise due to eddy currents induced in conductive 
system components (cables, collimator, cooling blocks, means of shielding, scintillators, etc.) 
placed inside of the magnet bore equipped with a gradient coil. Pulsed magnetic field gradients 
might also interfere with the electronic circuits and detectors of the SPECT device, disturbing the 
low amplitude signals within the SPECT acquisition chain (application specific integrated circuit 
(ASIC), data acquisition board (DAQ) etc.).  
 Radiofrequency (RF) energy transmission (B1+): RF transmission can induce temperature rise and 
functionality disturbances due to RF power deposition. RF might also interfere with the 
electronics and detectors of the SPECT device due to RF shielding deficits. Any RF emission of the 
SPECT device (for example: power supplies or preamplifier electronics) bears the potential to 
interfere with the MR device and compromise its (diagnostic) functionality through RF induced 
artifacts.  
 Movement and flow: Mechanical movement of components of the SPECT device can cause MR 
frequency shift due to eddy currents. Flow (for example: cooling fluids) in the field of view (FOV) 
to be imaged can cause MRI artifacts that present an impediment for diagnostic image quality. 
The implications feed into the (stationary) collimator design and the cooling strategy used for 
heat extraction from the SiPMs thermal pads. 
The literature primarily reports on evaluation of MR compatibility and safety of instruments for 
interventional MR procedures [53-56] and provides guidance for standardized test procedures [57-
60] that mainly focus on passive devices. A SPECT insert is an active device that differs from 
interventional MR devices/applications in many aspects. For the design of a synchronous clinical 
setup careful considerations need to be made to reduce if not eliminate electromagnetic coupling 
between the MR and SPECT device with the goal to assure SPECT/MR compatibility. These 
considerations should include legal regulations [61] and established norms [62, 63] but should also 
build upon a close interdisciplinary team work involving experts in electrical engineering, SPECT 
manufacturing, RF antenna design, MR physics, nuclear medicine and radiology. As a minimum, 
procedures for ensuring MR safety and compatibility should include the following assessments:   
Hard magnetic materials (also known as permanent magnets) including high carbon steels, barium, 
ferrite, alnico, samarium-cobalt alloys etc. are not MR-safe and should be strictly banned from any 
clinical SPECT design. This test can be conveniently performed by measuring the attraction force of a 
piece of metal plate placed in the vicinity of the material under investigation.  
 
Soft magnetic materials are not magnetized if not placed in the vicinity of a magnetic field. However, 
their susceptibility is very large and they exhibit forces and torques in the presence of a strong 
magnetic  field of a clinical MR scanner [64]. The test for soft magnetic materials is performed 
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according to the ASTM Standard F2052-06 [57] (American Section of the International Association 
for Testing Materials (ASTM)). For example WNiFe collimator material (alloy 1: =17.6 g/cm3, 
W=93%, Ni=5%, Fe=2%; alloy 2: =18.0 g/cm3, W=95%, Ni=3.5%, Fe=1.5%; Nuclear Fields 
International, Vortum-Mullem, The Netherlands) was found to be ferromagnetic and excluded from 
the collimator design. In comparison, collimator samples of Polymide/Tungsten (=11.0 g/cm3), Lead 
+ 4% Antimony (=11.03 g/cm3), Lead (=11.3g/cm3) and Tungsten (=19.3 g/cm3) are non-
magnetic. 
 
Nonmagnetic materials exhibit small magnetic susceptibility  so that no forces and torques are 
apparent when placed in a static magnetic field. To avoid any B0 perturbation induced by the 
magnetic susceptibility of the SPECT insert the ideal magnetic susceptibility would be SPECT insert = air 
= 0.36 x 10-6 [64] which is hard to achieve in practice. The effects of magnetization induced by non-
magnetic materials/objects used for the SPECT insert are largest at the surface of the object. 
Therefore it is prudent to place all components of the SPECT system outside of the field of view of 
the MR system for avoiding susceptibility gradient induced artifacts. The tests for magnetic 
susceptibility are based on the ASTM Standard F2119-07 [58] and on [65]. To achieve this goal a 
material probe together with a reference probe (e.g. copper) is placed in close proximity to an 
imaging phantom [65] filled with a solution [58]. MR scans are performed for multiple orientations 
to evaluate the severity and extent of magnetic field distortion and susceptibility artifacts induced by 
the material under investigation versus the reference probe (Figure 7).  
 
Frequency shift and free induction decay (FID) attenuation due to eddy currents induced by pulsed 
magnetic field gradients. Local eddy currents disturb B0 homogeneity resulting in frequency shift, T2* 
relaxation time shortening and FID attenuation. For eddy current and frequency assessment a 
reference FID/spectrum is acquired for an agarose phantom. For comparison, the object under test 
is placed in the magnet (resembling its position in the SPECT insert) followed by the acquisition of a 
test FID/spectrum. For both sets of measurements the delay between the pulsed magnetic field 
gradient and the FID acquisition is varied to determine the eddy currents time constant (Figure 8). 
Eddy current considerations have major implications for the design of the heat exchangers since 
commonly employed copper heat exchangers (which exhibit very good thermal conductivity 401 
W/mK) cannot be implemented. To overcome this limitation thermally conductive non-metallic 
materials, like ceramic material SHAPAL (Precision Ceramics, UK - thermal conductivity 92 W/mK) or 
thermally conductive plastic Coolpoly D5506 (Cool Polymers, USA - thermal conductivity 10 W/mK) 
are alternative candidates for the cooling block material. The latter is less cost intensive and can be 
easily modeled in complex forms with robust and reliable outcome. 
 
Heat extraction and spurious MR signals. From the MR perspective air cooling can be considered as 
an ideal candidate for heat extraction from the SiPMs thermal pads since air does not induce 
spurious MR signals. However, air cooling constitutes a severe challenge for flow and temperature 
stabilization needed for the SiPM’s performance. For this reason a water and glycol mixture (40 % - 
60%) is used for heat extraction from the cooling block. To reduce spurious MR signals the RF coil is 
shielded. Also, the tubes supplying and draining the heating blocks need to be routed outside of the 
excitation field of the RF coil to avoid spurious signals in the MR images. The remaining concern is 
spurious MR signals due to aliasing of parasitic signal obtained from the cooling fluid outside of the 
field of view into the field of view. This artifact is induced by parasitic excitation of regions outside of 
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the field of view due to the nonlinearity of the gradient coil, and commonly called “third arm 
artifact”. Parasitic excitation can be addressed by limiting the range of excitation and reception of 
the RF coil using a dome shaped design or by employing a bird cage design tailored to the brain. 
 
Mechanical vibration due to pulsed magnetic fields gradients. The literature is short of a 
standardized test given by ASTM or other bodies that is tailored for examining mechanical vibration 
induced by a device incorporated or inserted in an MR-scanner. Careful considerations should 
include the use of pressure and acceleration sensors. It is advised that the eigenfrequencies of the 
SPECT components do not match the frequencies of the magnetic field gradient switching schemes 
used for MRI to avoid strong coupling. 
 
Temperature changes due to pulsed magnetic fields gradients. Under normal conditions the heating 
due to pulsed magnetic field gradients in the kHz frequency range is negligible [66]. This may change 
if bulky electrically conductive objects (collimator, cooling blocks, ASIC etc.) are placed in the MR 
scanner. For temperature monitoring an object under test is placed either in air or in a gel phantom 
[59, 67] and positioned in the MR scanner according to its position within the SPECT system. 
Temperature probes are attached to the object and positioned in its vicinity. Pulsed magnetic field 
gradients are applied using clinical MR protocols including fast-spin echo, fast-gradient echo and 
echo-planar imaging sequences for fast and high duty cycle switching paradigms.  
 
Pulsed gradient fields can induce electrical voltages on the SPECT device components as well as all 
electrical cables connected to it. These voltage spikes interfere with device operation and can cause 
measurement artifacts in the form of spectral distortions and can even lead to a complete 
operational failure if voltages become too high. Electromagnetic simulations and bench 
measurements using pulsed magnetic field generators such as toroidal coils are performed to test 
problematic configurations and identify possible mitigation measures. 
 
SPECT/MR interferences due to RF transmission/emission. This compatibility issue can be two-fold: (i) 
interference of RF coil transmission with the functionality of the SPECT modules and (ii) interference 
of RF emission induced by the SPECT device with the RF chain of the MR scanner. To reduce RF 
interferences caused by the SPECT module it needs to be electro-magnetic compatibility (EMC) 
shielded. Efficiency of EMC shielding can be evaluated by placing the components of the SPECT 
electronics in a shielded box followed by measurements of RF spectra outside of the box (Figure 9). 
The RF coil itself is shielded, and additionally separated from the active components of the SPECT 
system by a collimator, which both reduce – if not eliminate – RF interferences with the SPECT 
device. For the evaluation of MR/SPECT interferences it is prudent to use a transmitted RF power 
that exceeds the limits given by the IEC guidelines by a factor of 3. For the assessment of SPECT/MR 
interference noise figures are acquired. For this purpose the component under investigation is 
placed in the MR system with the collimator (or alternative shielding) being installed. An RF coil and 
MR imaging phantom is placed inside of the collimator. A noise scan and clinical imaging protocols 
are performed while the component under test being in operation. These scans are benchmarked 
against reference data acquired without the component under investigation in the bore.  
 
Radiofrequency heating induced by the RF transmission. In current clinical MR scanners, integrated 
large volume body RF coils are commonly used for RF excitation. The large-volume excitation bodes 
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well for a uniform transmission field. Yet, this approach is not suitable for a clinical SPECT/MR setup 
due to the RF shielding provided by the collimator and other components of the SPECT insert. 
Instead, a small volume transmit transmit/receive RF coil tailored to the geometry of an average 
head and positioned inside the SPECT insert is employed. The RF power applied to this RF coil needs 
to be limited to meet the RF power deposition and specific absorption rate (SAR) limits governed by 
the IEC guidelines [68]. For this purpose careful electromagnetic field simulations need to be 
conducted in human voxel models. For validation, transmission field distributions obtained from 
these simulations need to be benchmarked against experimental B1+ maps [69, 70]. Since the 
integrated SPECT module is placed outside of the RF coil it is unlikely that the head coil of the MR 
scanner induces heating to the SPECT module that might cause a compatibility issue. 
 
Potential applications of clinical SPECT/MRI  
In general it is the authors’ opinion that multi-isotope SPECT imaging, with well-established 
radiopharmaceutical tracers of a variety of metabolic and molecular features could indeed provide 
useful synergies with function-related physio-metabolic MR imaging and spectroscopy including X-
nuclei MRI. Due to the massively multi-array possibilities of the resulting images synchronous 
SPECT/MRI realises insights hereto impossible for any other type of hybrid imaging methodologies 
(including PET/MRI). As nowadays fully quantitative SPECT reconstruction can be achieved, 
synchronous SPECT/MRI equipped with high temporal resolution acquisition, will be the method of 
choice for personalised therapy guidance and “radiomics”-based decisions (i.e. use of imaging 
parameters as a surrogate for reading out tumour biology). 
 
One goal of the current synchronous SPECT/MRI development is to aid in the clinical management of 
brain tumour patients. Assessment of treatment response in glioma patients is currently extremely 
challenging. Anatomical and contrast enhanced MRI remains the standard imaging modality at 
follow up but is associated with well documented problems in ascertaining response to treatment, 
particularly at early time points due to the phenomenon of pseudo-progression [71] associated with 
inflammation. Currently patients with imaging findings that suggest progression or pseudo-
progression are managed expectantly since the only approach to confirming the diagnosis is through 
continued clinical and radiological follow up. It is notable that FDG-PET imaging has not proven 
useful for this indication although amino-acid tracers may be more relevant and are still under 
investigation in this setting [72, 73]. Hence, based on current imaging approaches, patients who 
have true progression may be denied access to alternative treatments early and patients who will 
have an ultimately favourable outcome cannot be reassured. In the context of pseudo-progression, 
the earlier the imaging is carried out following treatment the less useful the data tend to be and to 
date there have been no successful approaches to monitor these patients during treatment. This is 
despite the fact that real-time assessment of treatment response, for example during radiotherapy 
or adjuvant chemotherapy could allow for selection of patients for treatment intensification at the 
time when treatment is likely to be most effective.  
 
The clinical use of simultaneous SPECT/MRI to directly help, assess (and thus predict) therapy 
monitoring will be most prominently present in the imaging and follow-up of local or systemic 
radionuclide therapy against post-surgical brain tumour remnants [74-76]. Dosimetry and efficacy 
control will be possible with a SPECT/MRI system as opposed to PET/MRI given that therapeutic 
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nuclides are mostly SPECT emitters too. Improved dosimetry in the tumour is indispensable to 
optimise radionuclide therapeutic procedures for reaching the highest possible tumour dose. 
Improved regional dosimetry is necessary to identify dose-related organ impairment risks, too.  
 
There is further potential for future use of specific radionuclide labelled peptides in targeted 
radionuclide therapy; provided that single photon emission is present in either the therapeutic 
radionuclide or an available analogue, then patient-specific dosimetry can be readily estimated. This 
would be an ideal use of the SPECT/MRI combination. In the future one can anticipate availability of 
compounds that are labelled either with gamma emitters for diagnostic purposes or with 
therapeutic radionuclides; the ability to plan and monitor therapy with these paired compounds has 
potential. If used for therapy the compound would be labelled with an alpha or beta emitter rather 
than gamma emitter; the gamma version would be used to plan subsequent personalized therapy 
using the alpha or beta emitter. One case is with 131I labelled compounds; 123I labelling can be used 
instead for therapy planning. The alternative use of 124I with PET is methodologically challenging and 
is limited by both general availability and dosimetric issues. One emerging example is targeted alpha 
therapy using 212Pb where 203Pb is proposed to be the surrogate dosimetry probe based on SPECT 
imaging [77]. 
 
Additional applications can be envisioned in research of the central nervous system (CNS). 
Functional MRI brain mapping studies combined with complementary, simultaneous SPECT readouts 
of neuro-receptor pathways using radiolabelled receptor ligands will be feasible with the system 
although PET/MRI will probably remain the preferred modality for these studies. In treatment of 
diseases of the CNS (especially dementia), intensive development of new therapies is underway. 
SPECT/MRI offers an outstanding opportunity for simultaneous blood perfusion imaging and 
determination of other disease indices such as dopamine transporter or neuro-inflammation-
associated parameters. Here Go/No-Go decisions of large investments (in pharmaceutical discovery 
and development) are dependent on early disease detection and the evaluation of treatment effect. 
But as suitable therapies are developed the demand for cost-effective tools will increase; SPECT/MRI 
may be the system of choice for wider-scale screening that may be indicated. 
Discussion  
There are several potential advantages offered by simultaneous acquisition of MRI and SPECT 
images, rather than simply sequential acquisition via adjacent gantries (or totally independent 
acquisition). The reduction of the overall scan time and associated improvements in patient comfort 
and compliance are important. The availability of registered datasets to assist localisation can be 
helpful as it is not always possible with separately acquired modalities, especially with highly specific 
radiotracers where many structures may not be visualised. However the potential to combine 
information from the two modalities so as to enhance diagnostic and prognostic information is 
particularly appealing. This can potentially extend beyond the improvement of SPECT quantification 
via motion or partial volume correction to the development of joint models that might enhance both 
SPECT and MRI-derived parameters. There is a strong case to evaluate the potential of this new 
multi-modality option.   
 
Both SPECT and MRI are lengthy procedures requiring patient cooperation, but restricting motion for 
lengthy periods can be a challenge, especially with certain brain conditions where movement control 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
PR
OO
FS
BJ
R 
UN
CO
RR
EC
TE
D 
11 
 
is affected. Motion effects can therefore be significant. Monitoring motion during SPECT acquisition 
is therefore very important and will allow correction of motion during reconstruction; this does 
imply that motion can be sufficiently well monitored during the complete SPECT acquisition, which 
should be possible using techniques being developed for PET/MRI [78-80]. For example, MRI 
navigator techniques can monitor and correct for motion for predefined regions such as the surface 
of the head, acquired in combination with most standard MRI techniques that may be selected for 
clinical studies (e.g. T1, T2). There are, however, challenges in accurately determining the rigid 
motion based on 6 degrees of freedom and alternative methods of motion tracking may be more 
appropriate, provided these can be implemented in the practical setting, with minimal interference 
to the normal clinically indicated MRI acquisition.  
 
Much of the work on partial volume correction (PVC) has been developed for PET. Traditionally, in 
the case of clinical systems, SPECT resolution is inferior to that of PET. PVC for SPECT is therefore 
more demanding but critical. Once again the techniques that have been developed for PET/MRI are 
easily adapted for the SPECT/MRI application. The availability of simultaneous SPECT and MRI data 
will greatly facilitate correction using post-reconstruction methods (see [81]), potentially reducing 
registration errors that affect PVC accuracy.  
 
A distinct advantage of SPECT over PET is the potential for simultaneous acquisition of multiple 
radiotracers labelled with different radionuclides. Similar techniques in PET rely on sequential use of 
short half-life radionuclides and extrapolation of time activity curves. The ability to combine multi-
tracer studies with multiple MRI pulse sequences extends the potential to better characterize tissue 
and evaluate treatment. A preclinical example of combined multi-radionuclide imaging and MRI is 
illustrated in Figure 10. Dual radionuclide imaging does require corrections for down-scatter, 
scattered photons from the higher energy emitter that are acquired in the energy window selected 
for the lower energy radionuclide. Correction is more complex in the case of CZT where a tail in the 
energy spectrum due to incomplete charge collection must also be accounted for [82-84]. A range of 
radiopharmaceuticals may be of interest for dual radionuclide imaging (see Table 1). 
 
There is still much to do to reach a stage of demonstrating robustness of SPECT/MRI and evaluating 
its clinical utility. Whether solid state detectors or SiPM readout systems will become the design of 
choice remains to be seen. Extension of design ideas to permit whole body acquisition may require a 
larger bore than typical of current MRI systems. Wide bore systems are clinically appealing to ease 
patient access and improve patient comfort, so this MRI system development may be dictated by 
independent clinical demands. Early experience suggests that clinical performance similar to that 
available on conventional SPECT systems should be possible with relatively compact 
detector/collimator combinations although further innovation may be needed to address sampling 
issues when the field of view is enlarged to accommodate the whole body.  
 
Conclusion 
The combination of SPECT and MRI is currently absent from the range of clinical multimodality 
systems although work is in progress to produce the first prototype. As in the case of PET/MRI, the 
combination of SPECT and MRI is attractive to patients who often have to undergo multiple lengthy 
imaging procedures. The dual radionuclide capability has particular appeal although the clinical need 
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for a simultaneous SPECT/MRI acquisition remains to be demonstrated. The development of 
appropriate technology remains challenging but ultimately may lead to more general superior SPECT 
performance.  
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Figure legends: 
Figure 1: Full preclinical ring populated with 10 gamma-detection modules. The mechanical 
structure also supports the cooling distribution tubes and the power and optical communication 
lines. The overall diameter of the insert is 20 cm. 
Figure 2: The 3-side-tilable SiPM arrays composing the planar detector FOV in the preclinical case. 
The dead detection area of the single array has been minimized to increase the amount of luminous 
signal collected. 
Figure 3: INSERT gamma-camera configured for preclinical SPECT. In the violet box, the 36-channel 
ASIC for signal readout and filtering is depicted. Digitized SPECT signals are transmitted through 
optical fibres. Temperature is stabilized at 0 °C by the cooling unit (an aluminum version of the unit 
is depicted). 
Figure 4: Planar irradiation profile for a 5 cm × 5 cm FOV of the preclinical INSERT detector module. 
(a) A lead grid of holes (0.5 mm in diameter, 2 mm pitch) is employed to collimate the gamma-rays. 
(b) experimental result for 99mTc: the event coordinates were reconstructed using a maximum 
likelihood method.  
Figure 5: a) Schematic diagram of the clinical system design with a partial ring of 20 detectors. The 
patient aperture of 33cm accommodates the MRI receive/transmit head coil. b) Schematic of 
complete SPECT insert in the MRI system. 
Figure 6: Multi-slit-slat (MSS) collimator corresponding to 3 detector units. The collimator consists of 
slats in the axial direction and an array of short slits with their apertures internal to the collimator 
surface. The figure shows a central slit (a) for each of the three subsections plus slits that are shared 
across adjacent detectors (b). 
Figure 7: Magnetic field distortion inside a uniform phantom due to the presence of a collimator 
block (Polyimide/Tungsten, ꝓ = 11.0 g/cm³) tested for the clinical SPECT/MR setup. The left image 
shows a uniform static magnetic field in the absence of the collimator block. For this setup a 
magnetic field dispersion ((f) of approximately 20 Hz was obtained across the slice. After placing 
the collimator block in close vicinity to the phantoms lower right corner the static magnetic field is 
significantly distorted (right) which manifests itself by a field dispersion across the slice of f120 Hz. 
Figure 8: Example of eddy current assessment using a reference FID (black line) obtained for an 
agarose phantom and pulsed magnetic field gradients placed along the read, phase and slice 
direction. For comparison, the object under test (Polymide/Tungsten sample (ꝓ=11.0 g/cm3) was 
placed in the magnet (resembling its position in the SPECT insert) followed by the acquisition of a 
test FID (blue and red line). For assessment of the eddy current time constants the delay between 
the pulsed magnetic field gradient and the FID acquisition was varied between 0.3 ms and 300 ms. 
Figure 9: Right) DAQ board mounted inside the EMC shielding test box for the evaluation of the 
SPECT/MR interference due to RF emission. Right) Closed test box being fully shielded. 
Figure 10a: 99mTc-DMSA(V) and Gd-enhanced gradient echo 3D sequence MRI visualizes peripheric, 
more perfused regions of the tumour to express more transporter proteins of phosphate ions 
related to energy metabolism. Also, the superior nature of SPECT/MRI with very high resolution and 
high soft tissue details/MRI-related functionality of the perfusion data readout is presented. 
Figure 10b: 125I-deoxy-uridine and Gd-enhanced gradient echo 3D sequence MRI visualizes central, 
less perfused regions of the tumour to express more DNA build-up (nucleoside incorporation). This 
image was taken synchronously with 99mTc-DMSA(V) images using an energy window centred at 28 
keV. 
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Tables 
Table 1: possible measurements using SPECT/MRI include a range of the MRI biomarkers (column 1) 
along with a 99mTc labelled compounds (column 3) and additional compounds with second 
radionuclide (column 5) which could be used interchangably.  Potential diversity of simultaneous 
measurement in the context of tumour characterization is well illustrated. 
MRI Application  SPECT1 Application 1 SPECT2 Application 2 
T1, 
Gadolinium 
enhancement 
Tumour site, 
blood brian 
barrier integrity  
99mTc-
DMSA(V) 
Phosphate 
transport  
201Tl-chloride Perfusion / 
glial activity 
(prognosis) 
T2 + FLAIR Invasiveness 99mTc-DTPA Blood brian 
barrier 
integrity 
111In-RGD 
peptide  
Angio-
neogenesis 
MRI perfusion 
+ T2 FLAIR 
Invasiveness, 
oedema 
99mTc-
Annexin-V 
Apoptosis 123I-CLINDE Histologic 
classification  
DWI + ADC 
additive: DTI 
Intra/extracellular 
oedema, pseudo-
progression 
99mTc- 
HMPAO 
Perfusion 111In-
Nimotuzumab 
Planning for 
specific 
treatment 
MR 
Spectroscopy 
Histologic 
classification 
99mTc-HL91 Hypoxia 123l- 
IodoUracyl 
Proliferation 
post therapy 
 
FLAIR fluid attenuated inversion recovery 
DWI diffusion weighted imaging 
ADC apparent diffusion coefficient 
DTI diffusion tensor imaging 
99mTc-DMSA(V) 99mTc labelled pentavalent dimercaptosuccinic acid 
99mTc-DTPA 99mTc labelled diethylenetriaminepentaacetic acid 
99mTc-HMPAO 99mTc labelled hexamethylpropyleneamine oxime 
99mTc-HL91 99mTc labelled 4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime 
123I-CLINDE 123I-labelled 6-chloro-2-(4′-iodophenyl)-3-(N,N-diethyl)imidazo[1,2-a]pyridine-3-
acetamide   
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